Deals: Page 21
-
Cancer biotech Tango to go public through $350M SPAC deal
Gilead, which expanded its research collaboration with Tango last year, will take part in a related private investment along with more than a dozen high-profile backers.
By Kristin Jensen • April 14, 2021 -
Courtesy of Sanofi
Sanofi buys an mRNA startup in another bet on 'off-the-shelf' cell therapy
Tidal Therapeutics is the second biotech developing more convenient cell therapies that the French pharma has recently acquired as part of a broader expansion in oncology.
By Ben Fidler • April 9, 2021 -
Amgen acquires a small biotech and its inflammatory disease research
The deal for Rodeo Therapeutics follows closely on the heels of the large biotech's buyout of cancer drug developer Five Prime.
By Kristin Jensen • March 31, 2021 -
FTC challenges Illumina's $7B Grail buyout amid new scrutiny of life science deals
The commission said the acquisition will "harm competition in the U.S. market" for early cancer detection tests.
By Nick Paul Taylor • March 31, 2021 -
Global Blood takes on more sickle cell drugs through Sanofi deal
Global Blood says the two acquired programs could complement Oxbryta, its marketed sickle cell drug that gained approval in late 2019.
By Jacob Bell • March 16, 2021 -
Brian Tucker/BioPharma Dive
FTC joins overseas antitrust regulators in reexamination of pharma M&A
Rebecca Kelly Slaughter, the commission's acting chair, indicated future reviews could look beyond measures of company size and market share.
By Jonathan Gardner • March 16, 2021 -
Elizabeth Regan/BioPharma Dive
Gilead, Merck combine forces in HIV
The rivals are now working together on oral and injectable treatments that combine their closely watched experimental drugs lenacapavir and islatravir.
By Jacob Bell • March 15, 2021 -
Taking a page from Celgene, Takeda builds and buys a cancer biotech
An agreement to acquire Maverick Therapeutics for up to $525 million has roots in a plan hatched by Takeda to emulate elements of Celgene's dealmaking strategy.
By Ben Fidler • March 9, 2021 -
Elizabeth Regan/BioPharma Dive
Biotech's deal refusals led to pricey buyout by Merck
Pandion rejected multiple offers by Merck to partner on or acquire the small biotech's research before accepting a $1.85 billion acquisition bid last month.
By Ned Pagliarulo • March 5, 2021 -
Amgen, with rare buyout, pays $1.9B for cancer biotech Five Prime
The acquisition marks a dramatic turnaround for Five Prime, which has in recent years struggled through setbacks, executive departures and layoffs.
By Ned Pagliarulo • March 4, 2021 -
Getty / Edited by BioPharma Dive
Doudna-founded biotech Caribou raises fresh funds to fuel gene editing pipeline
The CRISPR biotech raised $115 million in a Series C financing aimed at advancing its engineered cell therapy research.
By Kristin Jensen • March 3, 2021 -
Takeda takes full control of drug for rare epilepsies
A new agreement with Ovid Therapeutics has Takeda paying almost $200 million to secure global rights to soticlestat, an experimental treatment for certain brain diseases.
By Jacob Bell • March 3, 2021 -
Elizabeth Regan/BioPharma Dive
Merck to buy autoimmune drugmaker for $2B
The deal, which values Pandion Therapeutics at a more than 100% premium, would hand Merck a drug in early-stage testing for ulcerative colitis and lupus.
By Jacob Bell , Ben Fidler • Feb. 25, 2021 -
Beam, capitalizing on stock surge, buys gene therapy tools developer for $120M
Guide Therapeutics, the company Beam acquired, is working on ways to more efficiently deliver gene editing therapies into the body.
By Ned Pagliarulo • Feb. 23, 2021 -
Courtesy of Eli Lilly
Lilly wagers almost $1B on Rigel's drugs for immune and nervous systems
For $125 million up front, Lilly secures rights to a drug about to enter mid-stage testing for autoimmune and inflammatory diseases, as well as preclinical assets targeting the central nervous system.
By Jacob Bell • Feb. 18, 2021 -
Courtesy of CureVac
GSK expands CureVac vaccine partnership, changing course after setbacks
The U.K. drugmaker will help CureVac make 100 million doses of its coronavirus vaccine and join in developing a multivalent shot for 2022.
By Jonathan Gardner • Feb. 3, 2021 -
Jacob Bell/BioPharma Dive
Jazz Pharma to buy GW Pharma, maker of CBD-based epilepsy drug, for $7.2B
The deal gives Jazz, best known for its sleep disorder drugs, access to Epidiolex, the first prescription cannabidiol medicine approved by the FDA.
By Ned Pagliarulo • Feb. 3, 2021 -
Shifting strategy, Coherus buys rights to experimental cancer drug
The biosimilar maker will develop an immunotherapy rival to Merck's Keytruda via a deal with China's Junshi Biosciences.
By Jonathan Gardner • Feb. 1, 2021 -
Elizabeth Regan/BioPharma Dive
Horizon acquires Viela Bio for $3B in a windfall for AstraZeneca
AstraZeneca's decision to spin out Viela Bio in 2018 paid off with a drug approval, an initial public offering, and now an acquisition that will net the pharma close to $800 million.
By Jacob Bell , Ben Fidler • Feb. 1, 2021 -
Jacob Bell/BioPharma Dive
With latest deal, Merck wades into cell therapy for cancer
A small upfront payment gives Merck access to a program from Artiva Biotherapeutics that aims to create "off-the-shelf" CAR-NK cell therapies for solid tumors.
By Kristin Jensen • Jan. 28, 2021 -
Courtesy of Eli Lilly
Lilly strikes deal to acquire drug for chronic pain
The experimental treatment from Asahi Kasei Pharma adds to Lilly's pipeline of drugs for pain, including a non-opioid medicine now under review at the FDA.
By Ned Pagliarulo • Jan. 28, 2021 -
Courtesy of Eli Lilly
Lilly allies with Vir, GSK as coronavirus variants raise worries about antibody drugs
The emergence of new variants has made antibody drug combinations, which are harder for the virus to evade, more important and led to a unique partnership between a trio of drugmakers.
By Ben Fidler • Jan. 27, 2021 -
Courtesy of Eli Lilly
Lilly expands its cancer drug work with bet on dual-acting antibodies
An alliance with Merus, a Dutch biotech, continues Lilly's push to revitalize its oncology research under the leadership of former Loxo Oncology executives.
By Ben Fidler • Jan. 19, 2021 -
Dana-Farber launches venture fund targeting incurable cancers
Binney Street Capital plans to invest in eight to 10 companies over the next three years. Developing new drugs will be a core focus, though investments could also go toward health services, digital health or diagnostics.
By Jacob Bell • Jan. 15, 2021 -
Brian Tucker/BioPharma Dive
5 trends in biotech dealmaking to watch in 2021
Brain drugs, private equity players and blank-check companies are just some of the things deal experts say they'll be keeping an eye on this year.
By Jacob Bell • Jan. 13, 2021
Previous
